DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Dexcom bet on the high financial ceiling that exists by integrating its glucose monitoring capabilities into the ring, culminating in a $75m investment in Ō ...

DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.

Many DexCom, Inc. ( NASDAQ:DXCM ) insiders ditched their stock over the past year, which may be of interest to ...

That included stats showing Dexcom’s worldwide user base growing by about 25%, to more than 2.8 million customers. At the same time, Dexcom predicted its year-long sales would continue to grow ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

Baird has upgraded DexCom (NASDAQ:DXCM) to outperform from neutral, citing increasing confidence in the company's ability to return revenue growth to the low-to-mid teens by mid-2025. The ...

Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ...

On March 22, the jury found that Dexcom infringed one patent ... with global demand growing. CEO Robert Ford said in an earnings call in October that the potential for Abbott's FreeStyle Libre ...